TG Therapeutics Inc (NASDAQ:TGTX)’s share price hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $22.60 and last traded at $22.49, with a volume of 77879 shares traded. The stock had previously closed at $20.45.
Several research analysts recently weighed in on the company. Evercore ISI assumed coverage on TG Therapeutics in a research report on Friday, June 5th. They set an “outperform” rating and a $60.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating on shares of TG Therapeutics in a research report on Friday, May 29th. B. Riley reaffirmed a “buy” rating and issued a $37.00 target price on shares of TG Therapeutics in a research report on Monday, June 15th. BidaskClub raised TG Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, June 23rd. Finally, Cantor Fitzgerald upped their target price on TG Therapeutics from $19.00 to $35.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Seven investment analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and an average target price of $35.00.
The business has a 50-day simple moving average of $19.01 and a two-hundred day simple moving average of $14.21. The stock has a market cap of $2.24 billion, a price-to-earnings ratio of -10.79 and a beta of 2.47. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.39 and a quick ratio of 1.39.
TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.12). TG Therapeutics had a negative return on equity of 2,937.74% and a negative net margin of 124,230.27%. The business had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.04 million. As a group, equities analysts anticipate that TG Therapeutics Inc will post -1.38 earnings per share for the current fiscal year.
In other TG Therapeutics news, Director William James Kennedy sold 7,745 shares of the business’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $18.27, for a total transaction of $141,501.15. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 13.20% of the stock is owned by insiders.
Several large investors have recently made changes to their positions in TGTX. Great West Life Assurance Co. Can bought a new stake in TG Therapeutics during the fourth quarter valued at $59,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of TG Therapeutics by 37.5% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,032 shares of the biopharmaceutical company’s stock worth $59,000 after purchasing an additional 1,645 shares in the last quarter. Ameritas Investment Partners Inc. lifted its position in TG Therapeutics by 9.8% in the 1st quarter. Ameritas Investment Partners Inc. now owns 7,400 shares of the biopharmaceutical company’s stock valued at $73,000 after acquiring an additional 660 shares in the last quarter. Redhawk Wealth Advisors Inc. bought a new position in TG Therapeutics in the 1st quarter valued at about $98,000. Finally, Hikari Power Ltd bought a new position in TG Therapeutics in the 1st quarter valued at about $98,000. Institutional investors own 58.88% of the company’s stock.
About TG Therapeutics (NASDAQ:TGTX)
TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.
Further Reading: What is Call Option Volume?
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.